Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) released long-awaited Phase 3 results for its lead candidate, azetukalner (formerly XEN1101), sending its stock price soaring by 46.5%. The X-TOLE2 trial, which evaluated [...]
